Grifols (GIFLF) Common Equity (2009 - 2025)
Grifols' (GIFLF) quarterly Common Equity came in at $6.1 billion in Q4 2025, down 2.4% on a YoY basis from $6.3 billion in Q4 2024, and down 2.4% quarter-over-quarter from $6.3 billion in Q4 2024.
Analysis
Grifols (GIFLF) Common Equity (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Common Equity for 17 consecutive years, with $6.1 billion the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Common Equity fell 2.4% year-over-year to $6.1 billion; the trailing twelve-month figure through Dec 2025 stood at $6.1 billion (down 2.4% YoY), and the FY2025 full-year result was $6.0 billion, up 21368.7% from the prior year.
- Common Equity retreated to $6.1 billion in Q4 2025 per GIFLF's latest filing, from $6.3 billion in the prior quarter.
- Across five years, Common Equity topped out at $8.1 billion in Q4 2022 and bottomed at $6.1 billion in Q4 2025.
- Historically, Common Equity has averaged $7.3 billion across 5 years, with a median of $7.8 billion in 2021.
- The sharpest annual moves came in 2022 and 2024: Common Equity rose 3.73% in 2022, then fell 22.23% in 2024.
- Over 5 years, Common Equity stood at $7.8 billion in 2021, then increased by 3.73% to $8.1 billion in 2022, then dropped by 0.68% to $8.1 billion in 2023, then decreased by 22.23% to $6.3 billion in 2024, then dropped by 2.4% to $6.1 billion in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $6.1 billion, $6.3 billion, and $8.1 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 11.69 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 11.83 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 20.25 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 31.71 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 8.42 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 6.76 Bn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 18.85 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 4.92 Bn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 6.14 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 6.14 Bn |
| Dec 31, 2024 | 6.29 Bn |
| Dec 31, 2023 | 8.08 Bn |
| Dec 31, 2022 | 8.14 Bn |
| Dec 31, 2021 | 7.85 Bn |
| Dec 31, 2020 | 8.01 Bn |
| Sep 30, 2020 | 8.30 Bn |
| Mar 31, 2020 | 7.96 Bn |
| Dec 31, 2019 | 7.58 Bn |
| Sep 30, 2019 | 5.89 Bn |
| Dec 31, 2018 | 5.36 Bn |
| Sep 30, 2018 | 4.82 Bn |
| Jun 30, 2018 | 4.73 Bn |
| Mar 31, 2018 | 5.99 Bn |
| Dec 31, 2017 | 4.28 Bn |
| Jun 30, 2017 | 3.94 Bn |
| Dec 31, 2016 | 4.02 Bn |
| Sep 30, 2016 | 3.94 Bn |
| Jun 30, 2016 | 3.85 Bn |
| Mar 31, 2016 | 3.64 Bn |